These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30003452)

  • 21. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.
    Rangelova E; Wefer A; Persson S; Valente R; Tanaka K; Orsini N; Segersvärd R; Arnelo U; Del Chiaro M
    Ann Surg; 2021 Mar; 273(3):579-586. PubMed ID: 30946073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant chemotherapy is associated with improved survival in patients with left-sided pancreatic adenocarcinoma.
    Ocuin LM; Hardacre JM; Ammori JB; Rothermel LD; Mohamed A; Selfridge JE; Bajor D; Winter JM
    J Surg Oncol; 2020 Dec; 122(8):1595-1603. PubMed ID: 32844445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy.
    Newhook TE; Prakash LR; Soliz J; Hancher-Hodges S; Speer BB; Wilks JA; Bruno ML; Dewhurst WL; Arvide EM; Maxwell JE; Ikoma N; Kim MP; Lee JE; Katz MHG; Tzeng CD
    J Surg Oncol; 2021 Dec; 124(8):1381-1389. PubMed ID: 34398988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
    Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
    JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy.
    Roland CL; Katz MH; Tzeng CW; Lin H; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Vauthey JN; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S1221-8. PubMed ID: 26350371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy.
    Hue JJ; Sugumar K; Markt SC; Hardacre JM; Ammori JB; Rothermel LD; Winter JM; Ocuin LM
    Surgery; 2021 Jul; 170(1):207-214. PubMed ID: 33454134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study.
    Kurahara H; Shinchi H; Ohtsuka T; Miyasaka Y; Matsunaga T; Noshiro H; Adachi T; Eguchi S; Imamura N; Nanashima A; Sakamoto K; Nagano H; Ohta M; Inomata M; Chikamoto A; Baba H; Watanabe Y; Nishihara K; Yasunaga M; Okuda K; Natsugoe S; Nakamura M
    Langenbecks Arch Surg; 2019 Mar; 404(2):167-174. PubMed ID: 30649607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancreatic Consortium.
    Ogobuiro I; Collier AL; Khan K; de Castro Silva I; Kwon D; Wilson GC; Schwartz PB; Parikh AA; Hammill C; Kim HJ; Kooby DA; Abbott D; Maithel SK; Snyder RA; Ahmad SA; Merchant NB; Datta J
    Ann Surg Oncol; 2023 Mar; 30(3):1485-1494. PubMed ID: 36316508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perioperative Therapy for Borderline Resectable Pancreatic Cancer: What and When?
    Kim MP; Katz MHG
    Ann Surg Oncol; 2019 Jun; 26(6):1596-1597. PubMed ID: 30680479
    [No Abstract]   [Full Text] [Related]  

  • 30. Nationwide trends and outcomes of neoadjuvant chemotherapy in pancreatic cancer - an analysis of the Swedish national pancreatic cancer registry.
    Sternby H; Andersson B
    Scand J Gastroenterol; 2022 Nov; 57(11):1361-1366. PubMed ID: 35635264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
    Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
    Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy: A Single-Center Experience.
    Theijse RT; Stoop TF; Leenart PD; Lutchman KRD; Erdmann JI; Daams F; Zonderhuis BM; Festen S; Swijnenburg RJ; van Gulik TM; Schoorlemmer A; Sterk ALA; van Dieren S; Fariña A; Voermans RP; Wilmink JW; Kazemier G; Busch OR; Besselink MG;
    Ann Surg Oncol; 2024 Sep; 31(9):6180-6192. PubMed ID: 38954094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of resectability status in neoadjuvant treatment for pancreatic cancer.
    Sho M; Akahori T; Tanaka T; Kinoshita S; Nagai M; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Nakajima Y
    J Hepatobiliary Pancreat Sci; 2015 Jul; 22(7):563-70. PubMed ID: 25921623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery.
    Terlizzi M; Buscail E; Boussari O; Adgié S; Leduc N; Terrebonne E; Smith D; Blanc JF; Lapuyade B; Laurent C; Chiche L; Belleannée G; Le Malicot K; Trouette R; Pouypoudat C; Vendrely V
    Acta Oncol; 2021 Sep; 60(9):1114-1121. PubMed ID: 34197269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
    Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
    Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic Surgery recommended pathways for resectable and borderline resectable disease.
    Kamarajah SK; Chatzizacharias N; Hodson J; Marcon F; Kalisvaart M; Punia P; Ting Ma Y; Dasari B; Marudanayagam R; Sutcliffe RP; Muiesan P; Mirza DF; Isaac J; Roberts KJ
    ANZ J Surg; 2021 Jul; 91(7-8):1549-1557. PubMed ID: 33576568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. National Use of Chemotherapy in Initial Management of Stage I Pancreatic Cancer and Failure to Perform Subsequent Resection.
    Ellis RJ; Ho JW; Schlick CJR; Merkow RP; Bentrem DJ; Bilimoria KY; Yang AD
    Ann Surg Oncol; 2020 Mar; 27(3):909-918. PubMed ID: 31691112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in practice patterns and outcomes: A decade of sarcoma care in the United States.
    Song Y; Ecker BL; Tang R; Maggino L; Roses RE; DeMatteo RP; Fraker DL; Karakousis GC
    Surg Oncol; 2019 Jun; 29():168-177. PubMed ID: 31196484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The benefits of neoadjuvant therapy for patients with resectable pancreatic cancer: an updated systematic review and meta-analysis.
    Yang B; Chen K; Liu W; Long D; Wang Y; Liu X; Ma Y; Tian X; Yang Y
    Clin Exp Med; 2023 Nov; 23(7):3159-3169. PubMed ID: 37310659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma.
    Jiang W; Haque W; Verma V; Butler EB; Teh BS
    Acta Oncol; 2019 Sep; 58(9):1259-1266. PubMed ID: 31237185
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.